Ian_FV
Nov 7, 12:04 AM
6-K/8-K Important Update
$QNRX
Quoin Pharmaceuticals Ltd. announced positive interim results from its Phase 2/3 study of QRX003 for Netherton Syndrome, meeting primary and key secondary endpoints. The company secured up to
$50 million in private placement financing from healthcare-focused investors and received FDA clearance for its IND application for QRX003 in Peeling Skin Syndrome. Quoin also obtained FDA Rare Pediatric Disease and Fast Track Designations for PSS, along with Orphan Drug Designation from the European Medicines Agency.
More details at www.ianfv.com
0 replies